Immunocore/$IMCR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Primary listing
Employees
493
Headquarters
Website
Immunocore Metrics
BasicAdvanced
$1.6B
-
-$0.41
-
-
Price and volume
Market cap
$1.6B
52-week high
$39.33
52-week low
$23.15
Average daily volume
325K
Financial strength
Current ratio
5.893
Quick ratio
5.601
Long term debt to equity
111.877
Total debt to equity
112.351
Interest coverage (TTM)
-1.63%
Profitability
EBITDA (TTM)
-24.559
Gross margin (TTM)
92.32%
Net profit margin (TTM)
-5.70%
Operating margin (TTM)
-7.97%
Effective tax rate (TTM)
9.07%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
-1.69%
Return on equity (TTM)
-5.43%
Valuation
Price to revenue (TTM)
4.334
Price to book
3.99
Price to tangible book (TTM)
3.99
Price to free cash flow (TTM)
54.252
Free cash flow yield (TTM)
1.84%
Free cash flow per share (TTM)
0.568
Growth
Revenue change (TTM)
26.78%
Earnings per share change (TTM)
-63.34%
3-year revenue growth (CAGR)
57.14%
3-year earnings per share growth (CAGR)
-47.90%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Bulls say / Bears say
KIMMTRAK net product sales grew to $98.0 million in Q2 2025, marking a 30% year-over-year rise fueled by stronger U.S. community clinic adoption and entry into new countries.
Immunocore delivered net income of $5.0 million in Q1 2025 compared to a net loss of $24.4 million in Q1 2024, achieving its first profitable quarter and underscoring commercial momentum.
Cash, cash equivalents, and marketable securities reached $882.8 million as of June 30, 2025, up from $820.4 million at year-end 2024, giving the company a solid foundation to advance its pipeline.
Net loss remained at $10.3 million in Q2 2025 despite higher revenues, highlighting that the company returned to unprofitability after its turnaround in Q1.
Research and development expenses climbed to $69.0 million in Q2 2025, a 35% increase year-over-year, signaling a higher cash burn that may weigh on the balance sheet long-term.
More than 100% of product revenue still comes from KIMMTRAK, and key Phase 3 readouts like TEBE-AM (expected mid-2026) and PRISM-MEL-301 (dose selection in 2H 2025) are several quarters away, exposing Immunocore to single-product risk.
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Immunocore News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $1.6B as of November 06, 2025.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of November 06, 2025.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) does not currently have a Beta indicator.